InnoCare Reports the First Patient Dosing of ICP-488 in Clinical Trial for the Treatment of Psoriasis in China
Shots:
- The first patient has been dosed in the clinical trial evaluating ICP-488 (TYK2 JH2 allosteric inhibitor) in patients with mod. to sev. psoriasis in China. The ongoing study focuses to assess the safety & efficacy of ICP-488
- In the P-I trial, the single & multiple ascending doses have been completed with ICP-488 & showed a well-tolerated safety profile. The company seeks to advance the clinical development of innovative drugs & will offer better treatment options to patients with autoimmune diseases such as psoriasis early
- InnoCare is also developing autoimmune therapies with global frontier targets through B & T-cell pathways, incl. orelabrutinib (BTK inhibitor), ICP-332 (TYK2-JH1 inhibitor), ICP-488 (TYK2-JH2 inhibitor)
Ref: InnoCare | Image: InnoCare
Related News:- InnoCare’s Orelabrutinib Receives the NMPA’s Approval for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
